Myelofibrosis Treatment Algorithm 2018

Blood Cancer Journal - United States
doi 10.1038/s41408-018-0109-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

New Insight Into the Treatment of Primary Myelofibrosis

Cancer therapy & Oncology International Journal
2018English

Allogeneic Stem Cell Transplantation as Treatment for Myelofibrosis

Bone Marrow Transplantation
TransplantationHematology
2006English

What Is Pre-Fibrotic Myelofibrosis and How Should It Be Managed in 2018?

British Journal of Haematology
Hematology
2018English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research
2017English

Preclinical Rationale for TGF-β Inhibition as a Therapeutic Target for the Treatment of Myelofibrosis

Experimental Hematology
Cancer ResearchGeneticsHematologyMolecular BiologyCell Biology
2016English

Morphologic and Cytogenetic Differences Between Post-Polycythemic Myelofibrosis and Primary Myelofibrosis in Fibrotic Stage

Modern Pathology
Forensic MedicinePathology
2013English

Mayor Erythropoietic Response After Deferasirox Treatment in a Transfusion-Dependent Anemic Patient With Primary Myelofibrosis

Case Reports in Hematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy